がん治療のダイナミックな状況において、プレシジョン・メディシンの出現は治療パラダイムを変革し、個々の腫瘍の固有のパターンを利用するカスタマイズされたアプローチを提供しています。最近では、バイオテクノロジー企業や製薬会社のさまざまな利害関係者の好奇心により、画一的なモデルから、腫瘍の形成と進行に関与する主要な分子ドライバーの特定によって強調されたカスタマイズされた治療戦略に脚光が当てられています。その中でも、CD70タンパク質は有望な治療標的として浮上しており、がん治療やその他の治療の領域で大きな可能性を秘めています。
治療標的としてのCD70の研究は、がん患者にとってより効果的で、個別化され、カスタマイズされた治療法の選択肢のパノラマを握りしめています。当初、CD70タンパク質はT細胞とB細胞の活性化に関与していました。しかし、前臨床試験からの証拠を補強することは、CD70タンパク質がMAPキナーゼシグナル伝達経路とともにホスファチジルイノシトール-3キナーゼ(PI3K)の活性化を引き起こすことを意味します。このシグナル伝達経路の活性化は、さらに多くの転写因子の活性化をもたらし、それによって細胞増殖に関与する遺伝子の発現、生存、および癌疾患の原因となります。
前臨床試験から得られた研究エビデンスは、世界中のさまざまなステークホルダーの信頼と探究心を高めるのに役立ちます。そのため、多くの製薬会社やバイオテクノロジー企業がCD70療法の開発を計画し、臨床試験を開始しました。CD70タンパク質療法市場の発展を支援する重要な原動力の1つは、新しい研究を実施するための研究協力の増加です。多くの企業が研究機関や病院と手を携えて、CD70療法市場を前進させています。例えば、重慶精密バイオテクノロジーは、中国の南昌大学第一付属病院、浙江大学、山西ベスーン病院などの研究所や病院と提携し、余剰CD70の前臨床および臨床研究を実施しています。
目次
Table of Content
1 Unlocking Intricacies for CD70 Targeting Therapy
1.1 Overview to CD70 Targeting Therapy
1.2 Chronicle and Development of CD70 Targeting Therapy
1.3 The Prerequisite for CD70 Targeting Therapy
1.4 Dual Role of CD70 As Diagnostic and Prognostic Biomarker
2 Clinical Approaches For CD70 Targeting Therapy
2.1 Monoclonal Antibody
2.2 Bispecific Antibody
2.3 Tetraspecific Antibody
2.4 CAR T Cell Therapy
2.5 Antibody Drug Conjugate
2.6 CAR-NK Therapy
3 Combination Stratagems for CD70 Targeting Therapies
3.1 In Combination with Immunotherapy
3.2 In Combination with Epigenetic Modulators
3.3 In Combination with Targeted Therapy
3.4 In Combination with Oncolytic Virus Therapy
3.5 In Combination with Chemotherapy
4 CD70 Targeting Therapy By Indications: Current Clinical Development Trends and Innovations
4.1 Leukemia
4.2 Lymphoma
4.3 Gynecologic Cancer
4.4 Renal Cell Carcinoma
4.5 Lung Cancer
4.6 Autoimmune and Inflammatory Disease
4.7 Viral Infections
5 Global CD 70 Targeting Therapy Clinical Trials Overview
5.1 By Phase
5.2 By Country
5.3 By Company
5.4 By Indication
5.5 By Priority Status
5.6 Patient Segment
6 CD70 Targeting Therapy Candidates Granted FDA and EMA Designations
7 Global CD70 Targeting Therapy Current Market Trend and Developments
7.1 Current Market Outline
7.2 Future Market Forecast
8 CD70 Targeting Market Opportunity and Clinical Trends by Region
8.1 US
8.2 China
8.3 Europe
9 CD70 Targeting Therapy Development Platforms By Company and Technology
9.1 AlloCAR T Platform
9.2 Gamma Delta Cell Platform
9.3 Tailwind Platform
9.4 DARPin Platform
9.5 SIMPLE antibody platform
9.6 Potelligent Technology
10 Global CD70 Targeting Therapy Market Dynamics
10.1 Market Drivers
10.2 Market Challenges
11 Global CD 70 Targeting Therapies Clinical Trials Insight
11.1 Preclinical
11.2 Phase I
11.3 Phase I/II
11.4 Phase II
12 Competitive Landscape
12.1 Acepodia
12.2 Adaptimmune (TCR2 Therapeutics )
12.3 Adicet Bio
12.4 Allogene Therapeutics
12.5 Ambrx (Johnson and Johnson)
12.6 Chinook Therapeutics (Novartis)
12.7 CRISPR Therapeutics
12.8 ImmuneOnco Biopharma
12.9 Pfizer
12.10 Poseida Therapeutics
List of Figures
Figure 1-1: Introduction to CD70 Protein
Figure 1-2: Need of CD70 Therapy
Figure 1-3: CD70 - Diagnostic and Prognostic Marker
Figure 2-1: Research Headways targeting CD70 Therapy
Figure 3-1: Combinations of CD70 Therapy with Other Therapies
Figure 4-1: Molecular Partners - MP0533
Figure 4-2: MP0533 Phase I/II Study - Initiation and Completion Year
Figure 4-3: CD 70 CAR T Therapy Phase I/II Study - Initiation and Completion Year
Figure 4-4: Key Companies and Universities Enduring CD70 Clinical Research for Lymphoma
Figure 4-5: NCT06010875 Phase I Study - Initiation and Completion Year
Figure 4-6: Anti-hCD70 CAR transduced PBL Phase I/II Study - Initiation and Completion Year
Figure 4-7: Research by Allogene Therapeutics
Figure 4-8: ALLO-316 Phase Study - Initiation and Completion Year
Figure 4-9: CAR-NKT Cells Phase Study - Initiation and Completion Year
Figure 4-10: Vijay Goradia Donation to Advance CD70 Therapy for Renal Cell Carcinoma
Figure 5-1: Global - CD 70 Targeting Therapies Clinical Trials By Phase (Numbers), 2024
Figure 5-2: Global - CD70 Targeting Therapies Clinical Trials By Country (Numbers), 2024
Figure 5-3: Global - CD70 Targeting Therapies Clinical Trials By Company (Numbers), 2024
Figure 5-4: Global - CD70 Targeting Therapies Clinical Trials By Indication (Numbers), 2024
Figure 5-5: Global - CD70 Targeting Therapies Clinical Trials By Priority Status (Numbers), 2024
Figure 5-6: Global - CD70 Targeting Therapies Clinical Trials By Patient Segment (Numbers), 2024
Figure 7-1: Key Players in CD70 Market
Figure 7-2: Aspects Influencing CD70 Therapy Future
Figure 8-1: Allogene Therapeutics - ALLO-329
Figure 8-2: NCT05353530 Phase I Study - Initiation and Completion Year
Figure 8-3: SEA-CD70 Phase I Study - Initiation and Completion Year
Figure 8-4: CRISPR Therapeutics Clinical CD70 Therapy Pipeline
Figure 8-5: CTX131 Phase I/II Study - Initiation and Completion Year
Figure 8-6: Preclinical CD70 Therapy Candidates
Figure 8-7: Anti-CD70 CAR-T Cell Phase I Study - Initiation and Completion Year
Figure 8-8: CD70 CAR-T Phase I Study - Initiation and Completion Year
Figure 8-9: Chongqing Precision Biotech Research Collaborations to Initiate CD70 Therapy Clinical Trials
Figure 8-10: Aspects Influencing CD70 Therapy Market in Europe
Figure 9-1: Allogene Therapeutics - AlloCAR T Platform
Figure 9-2: Adicet Bio - Gamma Delta Cell Platform
Figure 9-3: ADI-270 - CD70 CAR andgamma;anddelta; T Cell Therapy
Figure 9-4: Catamaran Bio - Tailwind Platform
Figure 9-5: Molecular Partners - DARPin Platform
Figure 10-1: CD70 Therapy - Market Driver
Figure 10-2: CD70 Therapy - Market Challenges
